Felipe Samaniego is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 405 publications with 14,225 citations (h-index 63); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 5 Jul 2012.
Clinical trials
- Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma
Sponsor: M.D. Anderson Cancer Center
- Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
Sponsor: M.D. Anderson Cancer Center
- Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TG Therapeutics, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
51.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor35%Valacyclovir100%Part D≥13 patientsShort-acting sulfonamides16.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsCancer & immunology
48.8%Thalidomide Analog32.5%Revlimid100%Part D<11 patientsKinase inhibitor16.2%Imbruvica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2000–2013 per NIH RePORTER. The latest:
- Preservation of liver function through modulation of Fas-binding proteins
University of Tx Md Anderson Can Ctr
FY2013$190,588R03DK091490 - Cancer Cell Overexpression of Death Receptor Modulator
University of Tx Md Anderson Can Ctr
FY2013$161,516R21CA162278 - Cancer Cell Overexpression of Death Receptor Modulator
University of Tx Md Anderson Can Ctr
FY2012$206,190R21CA162278
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”